Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-05-18 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二一年年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of the 2021 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but focuses on the legal compliance and validity of the AGM process and voting outcomes. This type of document is typically associated with the Declaration of Voting Results & Voting Rights Announcements category, as it reports official voting results and confirms the legitimacy of the shareholder meeting proceedings. The document length (8170 characters) and content confirm it is not a brief announcement but a detailed legal opinion on the AGM voting results. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2022-05-18 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2021 Annual General Meeting (AGM) resolutions of Shenzhen BGI Genomics Co., Ltd. It details the date, attendance, voting results on various proposals including the 2021 annual report, board and supervisory reports, financial statements, profit distribution plan, auditor appointment, and other governance matters. The document is a formal announcement of the voting results and meeting proceedings rather than the full annual report or financial statements themselves. It includes detailed voting outcomes and legal opinions on the meeting's validity, which aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5298 characters, which is sufficient for a detailed voting result announcement. Therefore, the correct classification is DVA.
2022-05-18 Chinese
关于召开2021年年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2021 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items such as approval of the 2021 annual report, board and supervisory reports, financial statements, profit distribution plan, and auditor appointment. It also contains instructions for shareholder registration, proxy voting, and health safety measures due to the pandemic. The document is not the annual report itself but a notice and instructions related to the AGM. It does not contain financial statements or management discussion but is a formal notice to shareholders about the meeting and voting process. Therefore, it fits the category of AGM Information (AGM-R).
2022-05-13 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2021年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a 2021年度跟踪报告 (2021 Annual Tracking Report) by 中信证券股份有限公司 regarding 深圳华大基因股份有限公司. It includes detailed sections on sponsorship work overview, company and shareholder commitments, regulatory compliance, and supervisory measures taken by regulatory bodies such as the China Securities Regulatory Commission (CSRC). The content is comprehensive, covering governance, compliance, and operational oversight rather than just a brief announcement or a transcript. It is not a full annual report (10-K) but rather a detailed tracking report related to the company's regulatory and compliance status, sponsorship activities, and governance commitments. This type of document aligns with the category of Regulatory Filings (RNS) as it provides regulatory compliance information and supervisory updates without being a full financial report or earnings release. The document length (15,000 characters) and detailed content confirm it is not a mere announcement or certification but a substantive regulatory filing.
2022-05-10 Chinese
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the cancellation of a portion of the special accounts for raised funds. It details the background of the fundraising, the management and use of the raised funds, and specifically the cancellation of a fundraising special account after the related project was completed. The document includes specific account information, regulatory references, and procedural details about the cancellation. It does not contain financial statements or comprehensive financial data, nor is it a full report. Instead, it is a regulatory announcement about the status and management of fundraising accounts. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to updates on the company's fundraising and capital management activities.
2022-05-06 Chinese
联合资信评估股份有限公司关于终止深圳华大基因股份有限公司主体及相关债项信用等级的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a credit rating agency (联合资信评估股份有限公司) regarding the termination of credit ratings for Shenzhen BGI Genomics Co., Ltd. and its related bonds following the full redemption and delisting of those bonds. It references specific bond issues, redemption dates, and regulatory compliance for terminating the credit rating. The document is short (831 characters) and serves as a formal notice rather than a detailed financial report or audit. It does not contain financial statements or detailed analysis but is a regulatory announcement about credit rating status and bond delisting. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Delisting Announcement (DLST) because it focuses on credit rating termination rather than stock delisting, and it is not a full audit or financial report.
2022-04-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.